上海复旦复华科技股份有限公司 2023 年第一次临时股东大会会议资料 证券代码：600624 证券简称：复旦复华 上海复旦复华科技股份有限公司 2023 年第一次临时股东大会会议资料 二〇二三年九月 1 | 2023 | 年第一次临时股东大会议程 | 3 | | --- | --- | --- | | 2023 | 年第一次临时股东大会会议须知 | 4 | | 2023 | 年第一次临时股东大会议案表决办法 | 5 | | | 关于控股股东延期解决同业竞争承诺的议案 | 6 | 出席人员：1、2023 年 9 月 7 日下午交易结束后登记在册的本公司股东及其授权 委托人； 2、公司董事、监事、高管人员及聘任的股东大会见证律师。 会议议程： 一、介绍出席会议的股东人数及其代表的股份总数。 二、审议本次股东大会议案表决办法。 三、审议下列议案： 上海复旦复华科技股份有限公司 2023 年第一次临时股东大会会议资料 2023年第一次临时股东大会议程 现场会议召开时间：2023 年 9 月 15 日下午 2 点整 现场会议地点：上海市奉贤区茂园路 50 号 37 号楼 16 楼会议室 | 序号 | 议案名称 | | ...

证券代码：600624 证券简称：复旦复华 公告编号：临 2023-037 二、活动召开的时间、地点 上海复旦复华科技股份有限公司 关于参加 2023 年上海辖区上市公司集体接 待日暨中报业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 9 月 7 日（周四） 14:00-16:30 会议召开地点："全景路演"网站（http://rs.p5w.net）、全景财经 微信公众号或全景路演 APP 会议召开方式：网络远程 投资者可在业绩说明会召开前，识别公告中二维码，进入业绩说明会问 题征集专题页面提前留言提问。 上海复旦复华科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 日披露了《上海复旦复华科技股份有限公司 2023 年半年度报告》，为便于广大 投资者更深入全面地了解公司 2023 年中报业绩、公司治理、发展战略、经营状 况、融资计划、股权激励和可持续发展等投资者关心的问题，公司定于 2023 年 9 月 7 日(周四)14:00-16: ...

Financial Performance - The company's operating revenue for the first half of 2023 was RMB 350.21 million, a decrease of 6.43% compared to RMB 374.27 million in the same period last year[22]. - The net profit attributable to shareholders of the listed company was a loss of RMB 17.18 million, a decrease of 542.45% compared to a profit of RMB 3.88 million in the same period last year[22]. - The net cash flow from operating activities was RMB 11.13 million, down 75.11% from RMB 44.73 million in the previous year[22]. - The basic earnings per share for the first half of 2023 was -0.0251 yuan, a decrease of 540.35% compared to 0.0057 yuan in the same period last year[23]. - The weighted average return on net assets was -1.97%, a decrease of 2.39 percentage points compared to 0.42% in the previous year[23]. - The net profit attributable to shareholders in the pharmaceutical segment was CNY 18.09 million, an increase of 129.71% year-on-year[51]. - The software segment reported revenue of CNY 139.48 million, a decrease of 10.80%, with a net profit of CNY 12.46 million, down 6.13%[53]. - The total comprehensive income for the first half of 2023 was a loss of CNY 32.65 million, compared to a loss of CNY 12.03 million in the first half of 2022[152]. Cash Flow and Investments - The net cash flow from operating activities decreased by 75.11% due to a reduction in cash received from sales of goods and services[60]. - The net cash flow from investing activities decreased by 23.41 times, primarily due to new investments in two associate companies[60]. - The net cash flow from financing activities decreased by 160.10 times, mainly due to the recovery of minority shareholder equity from a controlling subsidiary[60]. - The company reported a cash inflow from financing activities of CNY 254 million in the first half of 2023, compared to CNY 236 million in the same period of 2022[156]. - The company reported an investment amount of 597.50 million RMB for the current period, marking a significant increase from 100.00 million RMB in the same period last year, representing a growth rate of 497.50%[72]. Industry Trends and Challenges - In the first half of 2023, the pharmaceutical manufacturing industry achieved operating income of CNY 1,249.6 billion, a year-on-year decrease of 2.9%, with total profit down by 17.1% to CNY 179.45 billion[28]. - The domestic generic drug market is under significant pressure due to the expansion of volume-based procurement and accelerated medical insurance negotiations[34]. - The pharmaceutical sector is experiencing a risk of price reductions due to centralized procurement practices, which may affect profit margins[86]. - Rising production costs are a concern, driven by stricter regulations and increased raw material prices, necessitating improved supplier management[87]. - The software division is facing risks from international policies affecting business operations in Japan, requiring strategic adjustments[88]. Regulatory and Compliance - The government has implemented a series of regulatory policies to strengthen the quality and safety supervision of drugs throughout their life cycle, effective from March 1, 2023[31]. - There were no significant risks or non-compliance issues reported during the period[8]. - The company’s subsidiary, Shanghai Fudan Fuhua Pharmaceutical Co., was listed as a key pollutant discharge unit, with all pollutants meeting discharge standards[97]. - The company has received environmental impact assessment approvals for all projects, with valid discharge permits until August 6, 2028[102]. Environmental and Sustainability Efforts - The company has taken measures to reduce carbon emissions through equipment upgrades and promoting green transportation[110]. - The company has upgraded its wastewater monitoring equipment, which is now in the acceptance phase, ensuring real-time data upload to the Shanghai environmental authority[99]. - The company operates a 6-ton gas boiler using clean natural gas, with emissions released through a 12-meter high exhaust stack[107]. - The company has established a comprehensive environmental emergency response mechanism, including specific plans for hazardous chemical accidents[108]. Corporate Governance and Shareholder Relations - The company did not propose any profit distribution or capital reserve conversion plans for the half-year period[95]. - The annual shareholders' meeting on June 21, 2023, had 10 shareholders present, representing 29.18% of the total shares[92]. - The company has committed to ensuring that all transactions with related parties are conducted at fair market prices[114]. - The company has pledged to reduce and standardize related party transactions to protect the interests of all shareholders[114]. Research and Development - The company is actively pursuing new product development, with two generic drug consistency evaluation approvals obtained in the first half of 2023[52]. - Research and development expenses decreased by 3.43% to CNY 19.61 million, reflecting a focus on efficiency[58]. Market Position and Competitive Edge - The company has established a strong market position in specialized drugs, with several products recognized as top products in the Shanghai pharmaceutical industry[36]. - Zhonghe Software has a strong competitive edge in the Japanese software outsourcing market, supported by a well-trained core development team of nearly 900 people[49].

证券代码：600624 证券简称：复旦复华 公告编号：临 2023-030 上海复旦复华科技股份有限公司 关于收到政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 经查询，截至 2023 年 8 月 7 日，上海复旦复华科技股份有限公司（以下简称"公 司"）全资及控股子公司新增与收益相关的政府补助 3,465,053.40 元。现将相关情 况公告如下： | 序号 | 获得补助的公司 | 项目内容 | 补助金额 | 银行到款时间 | 补贴依据 | 政府补助分类 | 计入损益的金 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 额 | | 1 | 重庆兴中和软件有限公司 | 社保补贴 | 468,709.05 | 2023.6.12 | 不适用 | 与收益相关 | 468,709.05 | | 2 | 重庆兴中和软件有限公司 | 2023 年企业享受 一次性吸纳就业 | 24,000.00 | 2023.6.12 | 不适用 ...

证券代码：600624 证券简称：复旦复华 公告编号：临 2023-031 公司于 2014 年 8 月 8 日收到上海市第二中级人民法院签发的（2014）沪二中民 一（民）初字第 1 号《应诉通知书》等相关法律文书，上海市第二中级人民法院已 受理原告陈宁迪、桂亚宁诉被告复旦大学、上海复旦复华科技股份有限公司所有权 1 上海复旦复华科技股份有限公司 涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 上海复旦复华科技股份有限公司（以下简称"公司"、"本公司"、"复旦复华" 或"复华公司"）于 2023 年 8 月 8 日收到上海市高级人民法院签发的（2022）沪民 终 463 号《民事判决书》，上海市高级人民法院就复旦大学诉公司其他与公司有关的 纠纷一案作出判决，现将相关情况公告如下： 一、案件的基本情况 上诉人：复旦大学 被上诉人：桂亚宁、陈宁迪、陈苏宁、尹小南、尹小申、尹小整 被上诉人：上海复旦复华科技股份有限公司 法院：上海市高级人民法院 案件所处的诉讼阶段：终审判决 上市公司所处的 ...

证券代码：600624 证券简称：复旦复华 公告编号：2023-026 上海复旦复华科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海复旦复华科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 年 6 月 28 日下午 14:00-15:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 6 月 28 日 下午 14:00-15:00 1 会议召开时间：2023 年 6 月 28 日(星期三) 下午 14:00-15:00 会议召开地 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥170,001,077.38, representing a decrease of 22.17% compared to the same period last year[5] - The net profit attributable to shareholders was ¥871,624.71, down 84.86% year-on-year[5] - Basic earnings per share decreased by 84.52% to ¥0.0013[5] - The net profit after deducting non-recurring gains and losses was -¥494,620.49, a decline of 122.88% year-on-year[5] - Net profit for Q1 2023 was ¥995,893.60, a decline of 83.7% from ¥6,112,221.17 in Q1 2022[20] - The company reported a comprehensive loss of ¥3,141,588.86 for Q1 2023, compared to a comprehensive income of ¥347,842.08 in Q1 2022[21] Cash Flow - The net cash flow from operating activities was -¥12,328,043.58, reflecting a significant decline of 1,226.92% compared to the previous year[5] - In Q1 2023, the net cash flow from operating activities was -12,328,043.58 RMB, a significant decline from 1,093,959.47 RMB in Q1 2022, indicating a negative cash flow trend[24] - Total cash inflow from operating activities decreased to 194,114,784.34 RMB, down 9.4% from 214,365,681.94 RMB in the same period last year[24] - Cash outflow from operating activities was 206,442,827.92 RMB, slightly lower than 213,271,722.47 RMB in Q1 2022, reflecting a 3.2% reduction[24] - The net cash flow from investing activities was -8,026,069.30 RMB, compared to a positive cash flow of 918,061.58 RMB in Q1 2022, indicating a shift towards increased investment expenditures[26] - The net cash flow from financing activities was -32,977,415.07 RMB, contrasting with a positive cash flow of 14,588,170.25 RMB in the previous year, highlighting increased cash outflows for debt repayment[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,808,630,169.10, a decrease of 2.78% from the end of the previous year[6] - The company's total liabilities amounted to ¥865,307,708.47, slightly down from ¥866,680,976.10 in the previous period[17] - Total current liabilities were RMB 592,563,981.87, compared to RMB 587,185,437.12, indicating a slight increase of approximately 0.6%[16] - The total non-current liabilities were ¥272,743,726.60, down from ¥279,495,538.98 in the previous period[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 70,399[10] - The largest shareholder, Shanghai Fengxian Investment (Group) Co., Ltd., held 18.74% of the shares, totaling 128,338,600 shares[10] Operational Insights - The company received a qualified opinion audit report from Lixin Accounting Firm for the reporting period[12] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] - Research and development expenses for Q1 2023 were ¥9,253,798.88, compared to ¥9,852,588.57 in Q1 2022, indicating a reduction in R&D spending[20] - The company invested 5,600,000.00 RMB in new projects during the quarter, reflecting a strategic focus on growth despite the overall cash flow challenges[26] Asset Composition - Current assets totaled RMB 1,047,584,011.51, down from RMB 1,094,143,021.25, indicating a decrease of about 4.3%[15] - Cash and cash equivalents decreased to RMB 254,018,224.60 from RMB 309,179,212.24, representing a decline of approximately 17.8%[15] - Accounts receivable stood at RMB 84,647,714.09, slightly down from RMB 86,489,881.84, a decrease of about 2.1%[15] - Inventory increased to RMB 665,078,263.15 from RMB 655,752,347.16, showing an increase of approximately 1.9%[15] - Short-term borrowings rose to RMB 385,000,000.00 from RMB 359,000,000.00, reflecting an increase of about 7.2%[16] - Long-term equity investments increased to RMB 24,343,196.67 from RMB 19,082,057.20, representing an increase of about 27.5%[16]

Financial Performance - The net profit attributable to shareholders for 2022 was a loss of RMB 3,609,733.76, compared to a loss of RMB 105,424,199.14 in 2021, indicating a significant improvement[6]. - Total revenue for 2022 was RMB 789,005,422.13, a decrease of 24.23% from RMB 1,041,335,675.14 in 2021[25]. - The net cash flow from operating activities for 2022 was RMB 28,146,459.61, down 38.25% from RMB 45,578,980.11 in 2021[25]. - The company's total assets at the end of 2022 were RMB 1,860,409,006.43, a decrease of 2.91% from RMB 1,916,227,337.20 at the end of 2021[25]. - The net assets attributable to shareholders decreased by 3.70% to RMB 882,402,904.68 at the end of 2022 from RMB 916,328,758.98 at the end of 2021[25]. - Basic earnings per share for 2022 were -0.005 yuan, an improvement from -0.154 yuan in 2021[24]. - The weighted average return on net assets for 2022 was -0.40%, compared to -10.60% in 2021, showing a recovery trend[24]. - The company does not plan to distribute profits or increase capital reserves due to the loss in 2022[6]. Revenue Breakdown - The pharmaceutical segment generated revenue of CNY 398.74 million, accounting for 50.54% of total revenue, but saw a decline of 17.80% year-on-year[33]. - The net profit for the pharmaceutical segment was CNY 36.60 million, down 24.01% from the previous year[33]. - Shanghai Zhonghe Software's revenue was CNY 283.65 million, a decrease of 10.48% year-on-year, accounting for 35.95% of the company's total revenue; net profit attributable to shareholders was -CNY 5.24 million[35]. - The total revenue of the park segment, including multiple subsidiaries, was CNY 81.06 million, a decrease of 61.80% year-on-year, accounting for 10.27% of the company's total revenue; net profit attributable to shareholders was CNY 20.85 million[37]. Challenges and Market Conditions - The company faced challenges due to drug bidding and procurement policies, impacting overall performance[34]. - The pharmaceutical segment faced challenges due to drug procurement policies, but the operational team implemented effective measures leading to a steady recovery in business performance starting from Q3 2022[55]. - The real estate sector faced significant challenges in 2022, with a decline in sales and an increase in buyer hesitation due to economic uncertainties and credit crises among property developers[92]. - The pharmaceutical industry is undergoing significant structural reforms, with increased regulatory pressures and rising raw material costs impacting profitability[139]. Research and Development - R&D efforts are being intensified for the consistency evaluation of generic drugs that were previously delayed[34]. - The company is focusing on expanding its product line in specialized medications, particularly in the fields of digestive, neurological, and oncology treatments[60]. - The company is focusing on the consistency evaluation of 289 listed products, with key evaluations completed for drugs such as Isosorbide Dinitrate Tablets and Tamoxifen Citrate Tablets in 2022[119]. - The company is currently conducting pharmaceutical research on several key projects, including the consistency evaluation of Isosorbide Dinitrate Tablets and Tamoxifen Citrate Tablets[124]. Investment and Assets - The company reported an increase in asset disposal income by 2,384.71%, mainly from the sale of properties and government buybacks[66]. - The total assets at the end of the reporting period were 1,860,000,000.00, with foreign assets accounting for 148,346,641.75, representing 7.97% of total assets[87]. - The fixed assets increased to 431,226,275.32, up 36.06% from 316,946,073.45 in the previous year, indicating ongoing investment in infrastructure[86]. - The company’s minority shareholder equity rose to 111,325,125.65, a 34.05% increase from 83,046,000.17, reflecting positive investor sentiment[86]. Corporate Governance - The company has established a sound corporate governance structure, ensuring compliance with relevant laws and regulations, and maintaining the interests of all shareholders[168]. - The board of directors held 10 meetings during the reporting period, ensuring independent opinions on major decisions[169]. - The supervisory board held 4 meetings, maintaining oversight of the company's operations and financial activities[170]. - The company adheres to strict information disclosure obligations, ensuring transparency and equal access to information for all shareholders[171]. Future Outlook - The company expects total revenue of 915 million yuan and operating costs of 525 million yuan for 2023[155]. - The company aims to enhance its business layout in the pharmaceutical, software, and park sectors, focusing on high-quality development[155]. - The company plans to explore new business and profit models while expanding its customer base and enhancing its brand recognition in the IT service sector[154]. - The company will closely monitor macroeconomic trends and national policies to proactively develop business plans and enhance profitability[165].

Financial Performance - The company's operating revenue for Q3 2022 was CNY 201,496,488.35, a decrease of 28.89% compared to the same period last year[5] - The net profit attributable to shareholders was CNY 426,466.64, down 95.00% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -1,009,402.76, a decline of 114.06% compared to the previous year[5] - The basic earnings per share for Q3 2022 was CNY 0.0006, a decrease of 95.16% year-on-year[6] - The net profit attributable to shareholders for the year-to-date decreased by 74.35%, primarily due to reduced profits from subsidiaries and the impact of pandemic-related rent reductions[10] - The company reported a significant decline in both basic and diluted earnings per share for the year-to-date, both down 74.29%[10] - Net profit for the first three quarters of 2022 was CNY 6,658,207.83, a decline of 67.6% compared to CNY 20,593,042.19 in 2021[24] - In Q3 2022, the company reported a total comprehensive income of -5,384,064.21 CNY, compared to 14,890,050.87 CNY in the same period of 2021, indicating a significant decline[25] - Basic and diluted earnings per share for Q3 2022 were both 0.0063 CNY, down from 0.0245 CNY in Q3 2021, reflecting a decrease of approximately 74.6%[25] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date was CNY 4,565,583.87, down 96.49% compared to the same period last year[6] - Cash flow from operating activities for the first three quarters of 2022 was 683,392,252.08 CNY, a decrease of 18.8% from 841,264,377.12 CNY in the same period of 2021[27] - The net cash flow from operating activities in Q3 2022 was 4,565,583.87 CNY, a sharp decline of 96.5% compared to 130,182,845.33 CNY in Q3 2021[28] - The company experienced a net cash outflow from investing activities of -2,381,565.16 CNY in the first three quarters of 2022, an improvement from -23,538,447.80 CNY in the same period of 2021[28] - Cash flow from financing activities generated a net inflow of 11,779,941.92 CNY in Q3 2022, contrasting with a net outflow of -44,779,674.87 CNY in Q3 2021[28] - The company's cash and cash equivalents at the end of Q3 2022 stood at 316,519,347.61 CNY, down from 365,435,943.49 CNY at the end of Q3 2021[29] - The company received 24,010,000.00 CNY from investments in Q3 2022, a significant increase from 490,000.00 CNY in the same period of 2021[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,910,543,058.60, a slight decrease of 0.30% from the end of the previous year[6] - The company's total assets as of the end of Q3 2022 amounted to CNY 1,910,543,058.60, slightly down from CNY 1,916,227,337.20 at the end of Q2 2022[20] - Total liabilities decreased to CNY 919,138,602.05 in Q3 2022 from CNY 916,852,578.05 in Q2 2022[20] - The company's total equity as of Q3 2022 was CNY 991,404,456.55, a slight decrease from CNY 999,374,759.15 in Q2 2022[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 66,671[13] - The largest shareholder, Shanghai Fengxian Investment (Group) Co., Ltd., holds 128,338,600 shares, accounting for 18.74% of total shares[13] - The company has no significant related party transactions among its top shareholders, ensuring independent shareholder actions[14] Operational Metrics - Total operating revenue for the first three quarters of 2022 was CNY 575,766,512.97, a decrease of 26.2% compared to CNY 779,807,392.75 in the same period of 2021[23] - Total operating costs for the first three quarters of 2022 were CNY 571,969,660.61, down 21.0% from CNY 724,746,800.15 in the previous year[23] - Research and development expenses for the first three quarters of 2022 were CNY 30,484,236.59, down from CNY 38,353,919.27 in the same period of 2021[23] - The company reported a decrease in sales expenses to CNY 123,772,518.95 in 2022 from CNY 176,212,129.75 in 2021[23] - The company recorded a loss in investment income of CNY 179,340.80 for the first three quarters of 2022, compared to a loss of CNY 1,613,605.50 in the same period of 2021[23] Audit and Project Management - The company has established a working group to address audit issues raised by the accounting firm regarding project settlement discrepancies[15] - The final project settlement price reached RMB 744 million, with significant cost increases attributed to various factors including labor and material price hikes[15] - The company has taken measures to actively engage with contractors to resolve outstanding audit confirmations[16]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥374.27 million, a decrease of 24.61% compared to ¥496.46 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥3.88 million, down 53.07% from ¥8.27 million in the previous year[18]. - The net cash flow from operating activities decreased by 40.60%, amounting to approximately ¥44.73 million compared to ¥75.29 million in the same period last year[19]. - Basic and diluted earnings per share for the first half of 2022 were both ¥0.0057, a decrease of 52.89% from ¥0.0121 in the previous year[18]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥882.40 million, a decrease of 3.70% from ¥916.33 million at the end of the previous year[18]. - Total assets at the end of the reporting period were approximately ¥1.90 billion, down 0.95% from ¥1.92 billion at the end of the previous year[18]. - The weighted average return on net assets for the first half of 2022 was 0.42%, a decrease of 0.33 percentage points from 0.75% in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately -¥3.46 million, compared to ¥7.47 million in the same period last year, reflecting a decrease of 146.39%[18]. Industry Overview - The pharmaceutical manufacturing industry achieved revenue of CNY 1,400.78 billion in the first half of 2022, a year-on-year decrease of 0.6%[25]. - The total profit for the pharmaceutical manufacturing industry was CNY 220.95 billion, down 27.6% year-on-year[25]. - The social retail sales of consumer goods in the first half of 2022 amounted to CNY 2,104.32 billion, a year-on-year decrease of 0.7%[26]. - The demand for pharmaceutical products continues to grow, driven by factors such as aging population and increased health awareness[26]. Company Strategy and Operations - The company focuses on specialized and characteristic drugs, particularly in the fields of digestive, neurological, anti-tumor, and circulatory system treatments[30]. - The company aims to expand market share for key products such as glutathione injection and dual-benefit tablets[30]. - The company has not disclosed any plans for new product development or market expansion in this report[6]. - The company is actively advancing new product development, including the registration of new drug projects and improving production capabilities[46][47]. - The company is focusing on expanding its market presence and improving its quality management systems to enhance operational efficiency[48][50]. Impact of COVID-19 - In the first half of 2022, the pharmaceutical company experienced a significant decline in operating performance due to the impact of COVID-19 outbreaks and centralized procurement policies, with production halted from mid-March to early June[32]. - The company's sales departments adapted to the pandemic by enhancing communication with commercial partners and utilizing online academic promotions to maintain market influence[32]. - The ongoing pandemic has led to operational challenges, including reduced demand for certain medications and disruptions in procurement and logistics[74]. Financial Position and Liabilities - Cash and cash equivalents at the end of the period amounted to CNY 350.79 million, representing 18.48% of total assets, an increase of 13.24% from the previous year[58]. - The company's long-term borrowings increased by 295.92% compared to the previous year, mainly due to additional long-term loans for project investment[58]. - The company's total liabilities increased, with short-term borrowings at CNY 453 million, accounting for 23.87% of total assets, an increase of 2.03% from the previous year[58]. - The company's total liabilities decreased to ¥882,400,646.17 at the end of the reporting period, compared to ¥999,374,759.15 at the end of the previous year[143]. Environmental Compliance - The company’s subsidiary, Shanghai Fudan Fuhua Pharmaceutical Co., Ltd., is classified as a key pollutant discharge unit, with various pollutants meeting the discharge standards[86]. - Wastewater discharge includes CODcr at 57.5 mg/L, which is below the standard limit of 500 mg/L, indicating compliance with environmental regulations[86]. - The company has established a comprehensive wastewater collection and treatment system, with real-time monitoring of pH, COD, and ammonia nitrogen data uploaded to the Shanghai Minhang District Ecological Environment Bureau[89]. - The company has implemented a complete environmental self-monitoring plan, regularly conducting environmental monitoring and uploading results to the national pollutant discharge permit management information platform[92]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 66,641, indicating a broad shareholder base[113]. - The company did not propose any profit distribution or capital reserve increase for the half-year period, with no dividends or stock bonuses planned[82]. - The top shareholder, Shanghai Fengxian Investment (Group) Co., Ltd., holds 128,338,600 shares, accounting for 18.74% of total shares[115]. Governance and Compliance - The company guarantees that its financial accounting department operates independently, with separate bank accounts and financial decision-making processes[101]. - The company will ensure that its senior management personnel are exclusively employed by the company and receive compensation solely from it[100]. - The company has made commitments to avoid conflicts of interest and protect the interests of all shareholders[101]. - The company will adhere to legal and regulatory requirements in all its operations and transactions[101].